US 11090332
Antigen specific mRNA cellular cancer vaccines
granted A61KA61K35/15A61K38/10
Quick answer
US patent 11090332 (Antigen specific mRNA cellular cancer vaccines) held by Regen Biopharma, Inc. expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regen Biopharma, Inc.
- Grant date
- Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K35/15, A61K38/10, A61K38/16